{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:15:15Z","timestamp":1792635315693,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jhepr.2021.100255","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T17:20:57Z","timestamp":1613928057000},"page":"100255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases"],"prefix":"10.1016","volume":"3","author":[{"given":"Arun J.","family":"Sanyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex M.","family":"DePaoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao D.","family":"Lieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2021.100255_bib1","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/hep.22789","article-title":"Bile acids: trying to understand their chemistry and biology with the hope of helping patients","volume":"49","author":"Hofmann","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100255_bib2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhepr.2021.100255_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hep.24681","article-title":"Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes","volume":"55","author":"Studer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100255_bib4","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.12688\/f1000research.12449.1","article-title":"Recent advances in understanding bile acid homeostasis","volume":"6","author":"Chiang","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.jhepr.2021.100255_bib5","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","article-title":"Molecular pathogenesis of cholestasis","volume":"339","author":"Trauner","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100255_bib6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100255_bib7","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2021.100255_bib8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100255_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/apt.15035","article-title":"Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD","volume":"49","author":"Caussy","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2021.100255_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151829","article-title":"Bile acids and dysbiosis in non-alcoholic fatty liver disease","volume":"11","author":"Mouzaki","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jhepr.2021.100255_bib11","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2337\/db18-1305","article-title":"FGF19 analog as a surgical factor mimetic that contributes to metabolic effects beyond glucose homeostasis","volume":"68","author":"DePaoli","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.jhepr.2021.100255_bib12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/liv.13201","article-title":"Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis","volume":"37","author":"Horvatits","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100255_bib13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13613-017-0272-7","article-title":"Circulating bile acids predict outcome in critically ill patients","volume":"7","author":"Horvatits","year":"2017","journal-title":"Ann Intens Care"},{"key":"10.1016\/j.jhepr.2021.100255_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhepr.2021.100255_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: the FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhepr.2021.100255_bib16","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Canc Res"},{"key":"10.1016\/j.jhepr.2021.100255_bib17","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2021.100255_bib18","article-title":"NGM313, a novel once-monthly activator of \u03b2-Klotho\/FGFR1c, significantly reduces hepatic steatosis and key biomarkers of nonalcoholic\u00a0steatohepatitis: results of a randomized, active-controlled clamp study in obese insulin resistant patients with NAFLD","volume":"69","author":"DePaoli","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100255_bib19","doi-asserted-by":"crossref","first-page":"28992","DOI":"10.1073\/pnas.2012073117","article-title":"Antibody-mediated activation of the FGFR1\/Klothobeta complex corrects metabolic dysfunction and alters food preference in obese humans","volume":"117","author":"Baruch","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100255_bib20","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100255_bib21","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100255_bib22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100255_bib23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100255_bib24","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100255_bib25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume":"70","author":"Rinella","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100255_bib26","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am J Transl Res"},{"issue":"Suppl","key":"10.1016\/j.jhepr.2021.100255_bib27","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1194\/jlr.R800026-JLR200","article-title":"Fifty years of advances in bile acid synthesis and metabolism","volume":"50","author":"Russell","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhepr.2021.100255_bib28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0022-2275(20)38331-0","article-title":"Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions","volume":"30","author":"Heuman","year":"1989","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhepr.2021.100255_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100255_bib30","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/1097-0142(197512)36:6<2401::AID-CNCR2820360619>3.0.CO;2-O","article-title":"Role of bile metabolites in colon carcinogenesis. Animal models","volume":"36","author":"Reddy","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2021.100255_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2021.100255_bib32","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100255_bib33","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100255_bib34","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100255_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL clinical Practice guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100255_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/19490976.2015.1127483","article-title":"Consequences of bile salt biotransformations by intestinal bacteria","volume":"7","author":"Ridlon","year":"2016","journal-title":"Gut Microbes"},{"key":"10.1016\/j.jhepr.2021.100255_bib37","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.27085","article-title":"Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2","volume":"60","author":"Liu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100255_bib38","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.ajpath.2018.05.015","article-title":"Conjugated bile acids promote invasive growth of esophageal adenocarcinoma cells and cancer stem cell expansion via sphingosine 1-phosphate receptor 2-mediated yes-associated protein activation","volume":"188","author":"Liu","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhepr.2021.100255_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0016-5085(93)90846-5","article-title":"Increased serum deoxycholic acid levels in men with colorectal adenomas","volume":"104","author":"Bayerdorffer","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100255_bib40","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0022-2275(20)34421-7","article-title":"Physicochemical properties of bile acids and their relationship to biological properties: an overview of the problem","volume":"25","author":"Hofmann","year":"1984","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhepr.2021.100255_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MOG.0b013e328352aab2","article-title":"The biliary HCO(3)(-) umbrella: experimental evidence revisited","volume":"28","author":"Beuers","year":"2012","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100255_bib42","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0140-6736(68)90235-3","article-title":"Bile-salts in small intestinal contents after ileal resection and in other malabsorption syndromes","volume":"1","author":"McLeod","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100255_bib43","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0016-5085(69)80032-6","article-title":"Increased ratio of glycine- to taurine-conjugated bile salts in patients with ileal disorders","volume":"56","author":"Garbutt","year":"1969","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100255_bib44","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0022-2275(20)38617-X","article-title":"Taurine increases bile acid pool size and reduces bile saturation index in the hamster","volume":"28","author":"Bellentani","year":"1987","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhepr.2021.100255_bib45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2012.02.014","article-title":"Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health","volume":"57","author":"Dilger","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100255_bib46","doi-asserted-by":"crossref","first-page":"19375","DOI":"10.1016\/S0021-9258(17)32178-6","article-title":"Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase","volume":"269","author":"Falany","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhepr.2021.100255_bib47","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.2337\/db13-0639","article-title":"Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids","volume":"62","author":"Haeusler","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jhepr.2021.100255_bib48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jhep.2020.03.011","article-title":"Hepatic fibrosis: a convergent response to liver injury that is reversible","volume":"73","author":"Wang","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100255_bib49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.taap.2015.01.015","article-title":"Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis","volume":"283","author":"Woolbright","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jhepr.2021.100255_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0168-8278(98)80208-0","article-title":"Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes","volume":"28","author":"Benz","year":"1998","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100255_bib51","first-page":"471","article-title":"Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria","volume":"19","author":"Krahenbuhl","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100255_bib52","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2005.01.007","article-title":"Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor","volume":"128","author":"Svegliati-Baroni","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100255_bib53","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.3390\/ijms19103043","article-title":"Secondary unconjugated bile acids induce hepatic stellate cell activation","volume":"19","author":"Saga","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhepr.2021.100255_bib54","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100255_bib55","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/hep.30969","article-title":"Is the total amount as important as localization and type of collagen in liver fibrosis attributable to steatohepatitis?","volume":"71","author":"Karsdal","year":"2020","journal-title":"Hepatology"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:26:51Z","timestamp":1762900011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921000318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2589555921000318"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100255","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100255"}}